ArticleJournal of arrhythmia2016
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban.
Article in Journal of arrhythmia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.Journal of thrombosis and thrombolysis · 2018Pooled it
- Comparison of therapeutic strategies in patients presenting with left atrial thrombus despite oral anticoagulation.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Management of left atrial appendage thrombus before percutaneous closure: Case report.HeartRhythm case reports · 2025Article
- Possible Factor Xa Resistance in a Patient Who Failed Apixaban and Rivaroxaban.Clinical case reports · 2024Article
- The Comparative Effectiveness and Safety of Different Anticoagulation Strategies for Treatment of Left Atrial Appendage Thrombus in the Setting of Chronic Anticoagulation for Atrial Fibrillation or Flutter.Cardiovascular drugs and therapy · 2023Article
- Prevalence and Rate of Resolution of Left Atrial Thrombus in Patients with Non-Valvular Atrial Fibrillation: A Two-Center Retrospective Real-World Study.Journal of clinical medicine · 2022Article
- Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?Medicina (Kaunas, Lithuania) · 2021Article
- Stroke prevention strategies in high-risk patients with atrial fibrillation.Nature reviews. Cardiology · 2021Review
- Left atrial appendage thrombus on full-dose dabigatran treatment: a case report.European heart journal. Case reports · 2020Article
- Apixaban successfully resolved a warfarin-resistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis.Anatolian journal of cardiology · 2019Article
- Prevalence and clinical characteristics associated with left atrial thrombus detection: Apixaban.World journal of cardiology · 2019Article
- Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report.Medicine · 2018Article
- Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report.European heart journal. Case reports · 2018Article
- Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.Journal of thrombosis and thrombolysis · 2017Article
- Reduced dose apixaban resolving dual cardiac chamber thrombi in a patient with ischaemic cardiomyopathy in sinus rhythm.BMJ case reports · 2017Article
- Review
- Left atrium mass in a patient with breast cancer: a case report.Journal of medical case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the existing thrombus, warfarin and novel anticoagulants have been used. However, there has been no clinical information regarding the difference of the effects of congealing the fibrinogenolysis system among these oral anticoagulants. Here, we report a case of persistent AF, in whom apixaban, factor Xa inhibitor resolved an LAA clot refractory to warfarin and direct thrombin inhibition. Factor Xa inhibitor, apixaban, could resolve the left appendage thrombosis refractory to warfarin and dabigatran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.